Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer

Author： Svendsen Mads N.   Brünner Nils   Christensen Ib J.   Ytting Henriette   Bentsen Camilla   Lomholt Anne F.   Nielsen Hans J.  

Publisher： Informa Healthcare

ISSN： 0036-5513

Source： Scandinavian Journal of Clinical and Laboratory Investigation, Vol.70, Iss.7, 2010-11, pp. : 503-511

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Significance of Nuclear Morphometry at the Invasive Front of T1 Colorectal Cancer and Relation to Expression of VEGF-A and VEGF-C

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 230-238

Karger

Access to resources Recommend Favorite

Guanylyl cyclase C as a biomarker in colorectal cancer

By Hyslop Terry   Waldman Scott A  

Biomarkers in Medicine, Vol. 7, Iss. 1, 2013-02 ,pp. : 159-167

Future Medicine

Access to resources Recommend Favorite

Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 1, 2018-01 ,pp. : 69-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 93, Iss. 3, 2017-05 ,pp. : 191-196

Karger

Access to resources Recommend Favorite

Soluble VEGFR‐1: A new biomarker of sorafenib‐related hypertension (i.e., sorafenib‐related is the compound adjective?)

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 478-479

John Wiley & Sons Inc

Access to resources Recommend Favorite